Vericel (VCEL) Total Current Liabilities (2010 - 2026)
Vericel (VCEL) posted Total Current Liabilities of $52.5 million for Q2 2026, up 11.4% sequentially from $47.2 million in Q1 2026, and up 27.72% YoY from $41.1 million in Q2 2025.
Analysis
Vericel (VCEL) Total Current Liabilities (2010 - 2026) Analysis & Trends
Vericel has reported Total Current Liabilities for 17 years, with the latest figure at $52.5 million in Q2 2026.
- Quarterly Total Current Liabilities rose 27.72% year-over-year to $52.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $52.5 million (up 27.72% YoY) and the FY2025 annual result came in at $49.1 million, down 2.26% from the prior year.
- Total Current Liabilities grew to $52.5 million in Q2 2026 per VCEL's latest filing, from $47.2 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $52.5 million in Q2 2026 and troughed at $21.7 million in Q1 2022.
- A 5-year average of $39.1 million and a median of $40.3 million in 2025 frame the typical range for Total Current Liabilities.
- The widest YoY moves for Total Current Liabilities: up 43.8% in 2022, down 6.45% in 2022.
- Over 5 years, Total Current Liabilities stood at $37.5 million in 2022, then climbed by 22.12% to $45.7 million in 2023, then gained by 9.92% to $50.3 million in 2024, then fell by 2.26% to $49.1 million in 2025, then rose by 6.88% to $52.5 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $52.5 million, $47.2 million, and $49.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 2.53 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 354.06 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 2.12 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.51 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 630.93 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn | 52.53 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 52.53 Mn |
| Mar 31, 2026 | 47.16 Mn |
| Dec 31, 2025 | 49.15 Mn |
| Sep 30, 2025 | 45.58 Mn |
| Jun 30, 2025 | 41.13 Mn |
| Mar 31, 2025 | 39.45 Mn |
| Dec 31, 2024 | 50.29 Mn |
| Sep 30, 2024 | 41.35 Mn |
| Jun 30, 2024 | 43.86 Mn |
| Mar 31, 2024 | 36.47 Mn |
| Dec 31, 2023 | 45.75 Mn |
| Sep 30, 2023 | 35.95 Mn |
| Jun 30, 2023 | 35.61 Mn |
| Mar 31, 2023 | 28.75 Mn |
| Dec 31, 2022 | 37.46 Mn |
| Sep 30, 2022 | 27.00 Mn |
| Jun 30, 2022 | 25.01 Mn |
| Mar 31, 2022 | 21.73 Mn |
| Dec 31, 2021 | 26.05 Mn |
| Sep 30, 2021 | 18.83 Mn |